| 30/03 | License agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjuga.. |  |
| 30/03 | Ebbing Bank Fears, GDP in Focus as Exchange-Traded Funds, Equity Futures Rise Premarket.. | |
| 30/03 | AstraZeneca Completes an Exclusive Global License Agreement with KYM Biosciences Inc | |
| 30/03 | AstraZeneca Completes Antibody Drug License Agreement With KYM Biosciences | |
| 30/03 | AstraZeneca signs exclusive global license deal with KYM Biosciences | |
| 30/03 | Stocks add to rebound; SSE ups earnings guidance | |
| 30/03 | AstraZeneca Completes KYM Solid Tumors Treatment Deal | |
| 30/03 | AstraZeneca Finalizes License Deal for KYM Biosciences' Potential Gastric Cancer Drug | |
| 30/03 | AstraZeneca Expands Facilities Management Tie-up With Compass Group | |
| 29/03 | Japan Had Weak Basis For Ordering 88 : audit | |
| 29/03 | Compass Group and Astrazeneca Expand Activities Focused on Innovation and Shared Succes.. | |
| 29/03 | UK's Hunt: Truss plans showed borrowing can't fund tax cuts | |
| 29/03 | Salipro Biotech publishes research in Scientific Reports on structure-function studies .. | |
| 29/03 | Boehringer's profit up 1.4% as Jardiance gains offset impairments | |
| 27/03 | Astrazeneca - Eplontersen demonstrated sustained benefit in Phase III trial for heredit.. | |
| 27/03 | Wall St set for higher open as SVB deal soothes frayed nerves | |
| 27/03 | Futures climb as banking crisis fears ebb after SVB deal | |
| 27/03 | Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyre.. | |
| 27/03 | Astrazeneca : Transaction by Person Discharging Managerial Responsibilities - Form 6-K | |
| 27/03 | Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyre.. | |
| 27/03 | AstraZeneca Says Phase 3 Trial of Eplontersen Drug Met Co-Primary Endpoints | |
| 27/03 | ANALYSE/Regeneron und Sanofi hoffen auf Milliarden dank COPD-Therapie |  |
| 27/03 | UK stocks finish higher as banks, AstraZeneca climb | |
| 27/03 | Novartis afirma que el fármaco contra el cáncer de mama Kisqali reduce el riesgo de rec.. |  |
| 27/03 | Ionis Pharmaceuticals Says Phase 3 Study of Eplontersen Meets Co-Primary Endpoints at 6.. | |
| 27/03 | AstraZeneca hails eplontersen; Enhertu wins another approval | |
| 27/03 | Novartis buoyed by trial success in early-stage breast cancer | |
| 27/03 | AstraZeneca, Ionis' Rare Genetic Disease Drug Sustains Transthyretin Protein Reduction .. | |
| 27/03 | Stocks called higher as banking crisis fears ease | |
| 24/03 | Calquence granted first regulatory approval in China for adults with previously treate.. | |
| 23/03 | Astrazeneca : 2022 Sustainability Highlights presentation | |
| 23/03 | Fed Rate Outlook Lifts Exchange-Traded Funds, Equity Futures Pre-Bell Thursday | |
| 23/03 | Beijing SL Pharma Registers Diabetes Drug | |
| 23/03 | Große Chance für Sanofi durch Studienerfolg bei Lungenkrankheit COPD | |
| 23/03 | AstraZeneca's Lymphoma Drug Granted Conditional Approval in China | |
| 23/03 | Sanofi y Regeneron presentan los datos de un fármaco contra el cáncer de pulmón del fum.. | |
| 23/03 | AstraZeneca's Calquence receives first approval in China | |
| 23/03 | AstraZeneca's Calquence Wins First Chinese Regulatory Nod for Rare Blood Cancer | |
| 22/03 | Astrazeneca : Marked up version of proposed new Articles to be considered by shareholders .. | |
| 22/03 | Astrazeneca : Publication of proposed new Articles to be considered by shareholders at the.. | |
| 22/03 | Astrazeneca : Proxy Form for 2023 AGM | |
| 22/03 | Astrazeneca : Notice of Annual General Meeting and Board Committee change - Form 6-K | |
| 22/03 | Syngenta: vendite record nel 2022 grazie ad elevati prezzi agricoli |  |
| 17/03 | Cornell University : Antibody fragment-nanoparticle therapeutic eradicates cancer | |
| 16/03 | MediWound Names Hani Luxenburg CFO | |
| 15/03 | Not out of the woods yet | |
| 15/03 | Analyst recommendations: AstraZeneca, Charles Schwab, Harley-Dav.. | |
| 15/03 | How GSK plans to replenish its depleted medicine cabinet | |
| 15/03 | Jefferies rates Future at 'hold'; Spirent upped | |
| 15/03 | Opiniones de los analistas del día: Inditex, Endesa, .. | |
| 14/03 | Gezondheid en farma: volop aan het consolideren |  |
| 14/03 | Advanced Gastric Carcinoma Pipeline Assessment of Active Pipeline Assets Segmented by S.. | |
| 14/03 | Opiniones de los analistas del día: Red Eléctrica, Si.. | |
| 13/03 | SVB shock could have chilling effect on British biotech sector | |
| 13/03 | Pfizer übernimmt Krebsspezialisten für 43 Milliarden Dollar | |
| 10/03 | Imfinzi significantly improved event-free survival in AEGEAN Phase III trial for patie.. | |
| 10/03 | Tagrisso demonstrated strong overall survival benefit in the ADAURA Phase III trial for.. | |
| 10/03 | Astrazeneca : launches call for entries to the 2023 global R&D Postdoctoral Challenge | |
| 09/03 | AstraZeneca Says Tagrisso Shows 'Strong' Overall Survival Benefit in Lung Cancer Phase .. | |
| 09/03 | Powell's Comments on Monetary Policy Continue to Weigh on Sentiment, Pressuring US Equi.. | |
| 09/03 | Key Jobs Data Anticipated as Exchange-Traded Funds, Equity Futures Slip Premarket Thurs.. | |
| 09/03 | Ovid Therapeutics Inc. - Studies Published in Cell Reports Medicine Validate the Potent.. | |
| 09/03 | TAGRISSO® (osimertinib) demonstrated strong overall survival benefit in the ADAURA Phas.. | |
| 09/03 | AstraZeneca PLC Announces Positive High-Level Results from the ADAURA Phase III Trial | |
| 09/03 | IMFINZI significantly improved event-free survival in AEGEAN Phase III trial for patien.. | |
| 09/03 | Astrazeneca plc Announces Imfinzi Significantly Improved Event-Free Survival in Aegean .. | |
| 09/03 | AstraZeneca hails trial results of cancer drugs Imfinzi and Tagrisso | |
| 09/03 | AstraZeneca Says Lung Cancer Combination Therapy 'Significantly' Improved Event-Free Su.. | |
| 09/03 | Chronic Kidney Disease : Africa's silent killer (By Viraj Rajadhyaksha) | |
| 09/03 | Astrazeneca meldet positive Studienergebnisse mit Imfinzi bei NSCLC | |
| 09/03 | AstraZeneca Imfinzi Phase 3 Trial Returns Positive Results | |
| 09/03 | AstraZeneca's Tagrisso Extends Lung Cancer Patients' Lives in Late-stage Study | |
| 09/03 | AstraZeneca's Imfinzi Prolongs Event-free Survival of Lung Cancer Patients in Phase 3 S.. | |
| 08/03 | Astrazeneca : Transactions by Persons Discharging Managerial Responsibilities - Form 6-K | |
| 08/03 | Astrazeneca : Transaction by Person Discharging Managerial Responsibilities - Form 6-K | |
| 07/03 | Personalis, AstraZeneca to Collaborate in Clinical Trials to Study Ultra-Sensitive Mole.. | |
| 07/03 | MÄRKTE EUROPA/Leichter - US-Notenbankpräsident Powell löst Zinsängste aus | |
| 07/03 | ENHERTU (fam-trastuzumab deruxtecan-nxki) showed clinically meaningful and durable resp.. | |
| 07/03 | Personalis, Inc. Announces to Continue Its Collaboration with AstraZeneca to Explore Ul.. | |
| 07/03 | Ionis Pharmaceuticals Says FDA Accepted for Review its Application for Nerve Disease Dr.. | |
| 07/03 | Ionis: FDA to Review Eplontersen in ATTRv-PN | |
| 06/03 | AstraZeneca, Daiichi Sankyo Say Enhertu Shows Responses Across Multiple Cancer Types in.. | |
| 06/03 | MIDDAY BRIEFING - Unternehmen und Märkte -2- | |
| 06/03 | ENHERTU® (fam-trastuzumab deruxtecan-nxki) Showed Clinically Meaningful and Durable Res.. | |
| 06/03 | Enhertu showed clinically meaningful and durable responses across multiple HER2-express.. | |
| 06/03 | AstraZeneca's Partner Daiichi Sankyo Says Enhertu Meets Objective Response Rate Target .. | |
| 06/03 | UK's FTSE 100 kicks off week on tepid note; miners fall | |
| 06/03 | Stocks called flat; AstraZeneca positive test results | |
| 06/03 | Astrazeneca meldet positive Ergebnisse für Krebsmittel Enhertu | |
| 06/03 | AstraZeneca cancer drug Enhertu show encouraging initial results for other tumours (Mar.. | |
| 06/03 | AstraZeneca Says Cancer Drug Enhertu Showed Positive Results | |
| 06/03 | AstraZeneca, Daiichi Sankyo's Enhertu Reduces Tumor Size in Mid-stage Study | |
| 06/03 | Astrazeneca and Daiichi Sankyo's Enhertu Met Prespecified Criteria for Objective Respon.. | |
| 02/03 | Viatris warns it will stop selling essential drugs in UK without changes to drug pricin.. | |
| 02/03 | Alexion advances commitment to transform patient outcomes in rare neurological diseases.. | |
| 02/03 | Merck, AstraZeneca Say US FDA's Panel to Review Cancer Drug Lynparza on April 28 | |
| 02/03 | US FDA to discuss AstraZeneca and Merck's Lynparza cancer drug combo | |
| 02/03 | Update on US regulatory review of Lynparza in combination with abiraterone for metasta.. | |
| 02/03 | AstraZeneca, Merck & Co.'s Supplemental New Drug Application for Lynparza up for Review.. | |
| 02/03 | Merck and AstraZeneca Provide Update on US Regulatory Review of LYNPARZA®? (Olaparib) f.. | |
Google
Twitter
Facebook
Apple
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Italiano
Nederlands (Nederland)
Nederlands (België)
bourse
Rapport
